Cargando…
COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia
The sickle cell mutation increases morbidity in those with sickle cell disease (SCD) and potentially sickle cell trait, impacting pulmonary, coagulation, renal, and other systems that are implicated in COVID-19 severity. There are no population-based registries for hemoglobinopathies, and they are n...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249598/ https://www.ncbi.nlm.nih.gov/pubmed/37083273 http://dx.doi.org/10.1097/MPH.0000000000002671 |
_version_ | 1785055593832120320 |
---|---|
author | Paulukonis, Susan T. Snyder, Angela Smeltzer, Matthew P. Sutaria, Ankit N. Hurden, Isabel Latta, Krista Chennuri, Swathi Vichinsky, Elliott Reeves, Sarah L. |
author_facet | Paulukonis, Susan T. Snyder, Angela Smeltzer, Matthew P. Sutaria, Ankit N. Hurden, Isabel Latta, Krista Chennuri, Swathi Vichinsky, Elliott Reeves, Sarah L. |
author_sort | Paulukonis, Susan T. |
collection | PubMed |
description | The sickle cell mutation increases morbidity in those with sickle cell disease (SCD) and potentially sickle cell trait, impacting pulmonary, coagulation, renal, and other systems that are implicated in COVID-19 severity. There are no population-based registries for hemoglobinopathies, and they are not tracked in COVID-19 testing. We used COVID-19 test data from 2 states linked to newborn screening data to estimate COVID outcomes in people with SCD or trait compared with normal hemoglobin. We linked historical newborn screening data to COVID-19 tests, hospitalization, and mortality data and modeled the odds of hospitalization and mortality. Georgia’s cohort aged 0 to 12 years; Michigan’s, 0 to 33 years. Over 8% of those in Michigan were linked to positive COVID-19 results, and 4% in Georgia. Those with SCD showed significantly higher rates of COVID-19 hospitalization than the normal hemoglobin Black cohort, and Michigan had higher rates of mortality as well. Outcomes among those with the trait did not differ significantly from the normal hemoglobin Black group. People with SCD are at increased risk of COVID-19–related hospitalization and mortality and are encouraged to be vaccinated and avoid infection. Persons with the trait were not at higher risk of COVID-related severe outcomes. |
format | Online Article Text |
id | pubmed-10249598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-102495982023-06-09 COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia Paulukonis, Susan T. Snyder, Angela Smeltzer, Matthew P. Sutaria, Ankit N. Hurden, Isabel Latta, Krista Chennuri, Swathi Vichinsky, Elliott Reeves, Sarah L. J Pediatr Hematol Oncol Medical Progress The sickle cell mutation increases morbidity in those with sickle cell disease (SCD) and potentially sickle cell trait, impacting pulmonary, coagulation, renal, and other systems that are implicated in COVID-19 severity. There are no population-based registries for hemoglobinopathies, and they are not tracked in COVID-19 testing. We used COVID-19 test data from 2 states linked to newborn screening data to estimate COVID outcomes in people with SCD or trait compared with normal hemoglobin. We linked historical newborn screening data to COVID-19 tests, hospitalization, and mortality data and modeled the odds of hospitalization and mortality. Georgia’s cohort aged 0 to 12 years; Michigan’s, 0 to 33 years. Over 8% of those in Michigan were linked to positive COVID-19 results, and 4% in Georgia. Those with SCD showed significantly higher rates of COVID-19 hospitalization than the normal hemoglobin Black cohort, and Michigan had higher rates of mortality as well. Outcomes among those with the trait did not differ significantly from the normal hemoglobin Black group. People with SCD are at increased risk of COVID-19–related hospitalization and mortality and are encouraged to be vaccinated and avoid infection. Persons with the trait were not at higher risk of COVID-related severe outcomes. Lippincott Williams & Wilkins 2023-05 2023-03-20 /pmc/articles/PMC10249598/ /pubmed/37083273 http://dx.doi.org/10.1097/MPH.0000000000002671 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Medical Progress Paulukonis, Susan T. Snyder, Angela Smeltzer, Matthew P. Sutaria, Ankit N. Hurden, Isabel Latta, Krista Chennuri, Swathi Vichinsky, Elliott Reeves, Sarah L. COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia |
title | COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia |
title_full | COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia |
title_fullStr | COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia |
title_full_unstemmed | COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia |
title_short | COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia |
title_sort | covid-19 infection and outcomes in newborn screening cohorts of sickle cell trait and sickle cell disease in michigan and georgia |
topic | Medical Progress |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249598/ https://www.ncbi.nlm.nih.gov/pubmed/37083273 http://dx.doi.org/10.1097/MPH.0000000000002671 |
work_keys_str_mv | AT paulukonissusant covid19infectionandoutcomesinnewbornscreeningcohortsofsicklecelltraitandsicklecelldiseaseinmichiganandgeorgia AT snyderangela covid19infectionandoutcomesinnewbornscreeningcohortsofsicklecelltraitandsicklecelldiseaseinmichiganandgeorgia AT smeltzermatthewp covid19infectionandoutcomesinnewbornscreeningcohortsofsicklecelltraitandsicklecelldiseaseinmichiganandgeorgia AT sutariaankitn covid19infectionandoutcomesinnewbornscreeningcohortsofsicklecelltraitandsicklecelldiseaseinmichiganandgeorgia AT hurdenisabel covid19infectionandoutcomesinnewbornscreeningcohortsofsicklecelltraitandsicklecelldiseaseinmichiganandgeorgia AT lattakrista covid19infectionandoutcomesinnewbornscreeningcohortsofsicklecelltraitandsicklecelldiseaseinmichiganandgeorgia AT chennuriswathi covid19infectionandoutcomesinnewbornscreeningcohortsofsicklecelltraitandsicklecelldiseaseinmichiganandgeorgia AT vichinskyelliott covid19infectionandoutcomesinnewbornscreeningcohortsofsicklecelltraitandsicklecelldiseaseinmichiganandgeorgia AT reevessarahl covid19infectionandoutcomesinnewbornscreeningcohortsofsicklecelltraitandsicklecelldiseaseinmichiganandgeorgia |